| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | - | - | -100.0% |
| Operating Income | ¥-9.2B | ¥-8.4B | -9.6% |
| Ordinary Income | ¥-9.2B | ¥-8.4B | -10.1% |
| Net Income | ¥-9.9B | ¥-8.5B | -17.4% |
| ROE | -78.5% | -37.5% | - |
FY2025 annual results show a deepening loss position with Operating Loss of 9.2B yen (YoY -9.6% deterioration from prior year loss of 8.4B yen), Ordinary Loss of 9.2B yen (YoY -10.1% from prior year loss of 8.4B yen), and Net Loss of 9.9B yen (YoY -17.4% from prior year loss of 8.5B yen). Basic EPS deteriorated to -85.59 yen from -72.94 yen in the prior year. Total Assets increased 5.9B yen to 29.4B yen, primarily driven by cash accumulation from debt financing, while Total Equity declined sharply by 9.9B yen to 12.7B yen due to accumulated losses. The company maintains substantial cash reserves of 27.9B yen despite negative operating cash flow of 9.2B yen, supported by Financing CF inflow of 15.0B yen mainly from bond issuance. The full-year forecast projects further deterioration with Operating Loss expected to reach 15.2B yen.
Revenue data is not disclosed in the XBRL filing, precluding direct top-line analysis. The bottom-line performance shows continued operational losses with SG&A expenses of 9.2B yen representing the primary cost structure. Operating Loss of 9.2B yen deteriorated 9.6% YoY, indicating that cost containment efforts have not offset the revenue challenges. Non-recurring factors include impairment losses of 0.70B yen recorded during the period, contributing to asset value adjustments. The gap between Ordinary Loss of 9.2B yen and Net Loss of 9.9B yen is approximately 0.7B yen, primarily attributable to tax effects and impairment charges flowing through to the bottom line. Interest expense remained minimal at 0.01B yen despite the bond issuance, suggesting favorable financing terms. The company exhibits a revenue decline/profit decline pattern, with operational losses expanding year-over-year while the revenue base remains undisclosed but appears to be under pressure based on the deteriorating loss profile.
[Profitability] ROE of -78.5% reflects severe profitability challenges with net losses eroding shareholder equity. Operating margin cannot be calculated due to undisclosed revenue, but the absolute operating loss of 9.2B yen against SG&A of 9.2B yen indicates zero gross profit generation or negative gross margins. [Cash Quality] Cash and deposits of 27.9B yen provide robust liquidity with short-term debt coverage ratio of 27.4x against current liabilities of 1.0B yen. Operating CF to net income ratio of 0.92x shows operational cash outflows are closely aligned with accounting losses, confirming cash-backed earnings quality without material accruals distortion. [Investment Efficiency] Asset turnover cannot be assessed without revenue data. Total assets increased 24.9% YoY to 29.4B yen, driven primarily by cash accumulation rather than productive asset expansion. [Financial Health] Equity ratio of 43.0% declined substantially from prior year levels due to equity erosion from losses. Current ratio of 2,840% demonstrates exceptional short-term liquidity. Debt-to-equity ratio of 1.32x reflects increased leverage following bond issuance of approximately 15.0B yen, with non-current liabilities reaching 15.7B yen comprising 94% of total liabilities.
Operating CF of -9.2B yen represents 0.92x of net loss of -9.9B yen, indicating operational cash burn is closely aligned with accounting losses and confirming the absence of material non-cash earnings manipulation. The cash conversion aligns with the loss-making operational structure. Investing CF of -0.5B yen was minimal, with CapEx of only 0.1B yen suggesting limited growth investment and asset maintenance mode. Financing CF of 15.0B yen was the primary cash source, predominantly from bond issuance of approximately 15.0B yen, providing the capital buffer to sustain operations during the loss period. FCF of -9.7B yen reflects continued cash consumption from core operations. Despite negative operational cash generation, cash and deposits increased 5.2B yen to 27.9B yen, entirely attributable to debt financing inflows exceeding operational outflows and minimal investment activity. The current liquidity position of 27.9B yen against current liabilities of 1.0B yen provides a coverage ratio of 27.4x, ensuring near-term solvency despite operational cash burn.
Ordinary Loss of 9.2B yen compared to Operating Loss of 9.2B yen shows minimal non-operating impact, with net non-operating contribution near zero. Interest expense of 0.01B yen remains immaterial despite the bond issuance of 15.0B yen, likely due to timing of issuance late in the fiscal year or favorable interest terms. Non-operating income components are minimal and represent less than 1% of total assets, consisting primarily of financial income and expenses that net to approximately zero. The gap between Ordinary Loss of 9.2B yen and Net Loss of 9.9B yen of approximately 0.7B yen is explained by impairment losses of 0.70B yen recorded as a special loss item, representing non-recurring asset write-downs. Operating CF of -9.2B yen closely tracks Net Loss of -9.9B yen with a ratio of 0.92x, indicating that losses are cash-backed without significant accrual-based earnings manipulation. The alignment of operating cash outflows with accounting losses confirms earnings quality from a cash realization perspective, though the absolute negative performance warrants significant concern for operational sustainability.
Full-year forecast indicates Operating Loss of 15.2B yen, Ordinary Loss of 15.5B yen, and Net Loss of 16.2B yen, with Basic EPS projected at -58.97 yen. The current annual results show Operating Loss of 9.2B yen, representing 60.5% progress against the 15.2B yen full-year loss forecast, suggesting the loss trajectory is tracking below the full-year guidance. However, since these are annual results being compared to full-year forecasts, this indicates the company has revised expectations downward during the fiscal year, with actual annual losses coming in better than the latest full-year forecast by approximately 6.0B yen at the operating level. The forecast assumes continued operational challenges with no immediate path to profitability. Dividend per share is forecast at zero, consistent with the loss-making status and capital preservation needs.
Annual dividend is zero for both interim and year-end periods, unchanged from the prior year. Payout ratio is not applicable given the net loss position of 9.9B yen and negative retained earnings. No share buyback activity is disclosed during the period. Total return ratio is 0% as no capital is being returned to shareholders through either dividends or buybacks. The zero dividend policy aligns with the need to preserve cash resources given negative operating cash flow of 9.2B yen and ongoing operational losses, despite substantial cash reserves of 27.9B yen that were bolstered through debt financing rather than operational generation.
Operational sustainability risk remains the primary concern with Operating Loss of 9.2B yen and negative Operating CF of 9.2B yen indicating the business model has not achieved commercial viability. SG&A expenses of 9.2B yen match the operating loss, suggesting zero or negative gross margins that require fundamental business model restructuring. Refinancing and debt servicing risk has emerged with non-current liabilities increasing to 15.7B yen, predominantly bonds payable of 15.0B yen. While interest expense remains minimal at 0.01B yen currently, the maturity schedule and refinancing conditions for the 15.0B yen bond will be critical, particularly if operational losses continue to erode equity from the current 12.7B yen level. Asset impairment risk is evidenced by the 0.70B yen impairment charge recorded in the current period, with additional impairment potential if operational performance does not improve, particularly given the limited disclosure on asset composition and revenue-generating capacity of current assets beyond the 27.9B yen cash position.
[Industry Position] (Reference - Proprietary Analysis) The company operates in the pharmaceutical sector where typical profitability and financial health metrics differ significantly from this company's current position. Due to limited comparable benchmark data availability and the company's pre-revenue or minimal revenue stage, direct industry median comparisons are constrained. However, general industry observations indicate that pharmaceutical companies typically maintain ROE in positive territory ranging from 5-15% for established players, substantially above this company's -78.5%. Equity ratios in the pharmaceutical industry typically range from 50-70% for stable operators, compared to this company's 43.0% which reflects equity erosion from losses. Operating margins for commercial-stage pharmaceutical companies generally range from 15-30%, whereas this company reports negative operating margins with losses of 9.2B yen. The company's current financial profile suggests it is in a development or pre-commercial stage requiring capital infusion, as evidenced by the 15.0B yen bond financing. Cash holdings of 27.9B yen relative to total assets of 29.4B yen (95% cash composition) indicate a financial holding pattern distinct from operating pharmaceutical companies with substantial tangible and intangible asset bases. Interest coverage is not meaningful in loss-making scenarios, but the minimal interest expense of 0.01B yen suggests favorable debt terms or recent timing of the bond issuance.
Financial restructuring and capital allocation strategy represents the key observable trend, with the company raising 15.0B yen through bond financing to build cash reserves to 27.9B yen, providing an estimated 3 years of operational runway at current cash burn rates of approximately 9.2B yen annually. This suggests management is prioritizing liquidity preservation and extending the time horizon to achieve operational breakeven or secure additional capital. Operational performance trajectory shows deteriorating fundamentals with operating losses expanding 9.6% YoY to 9.2B yen despite minimal capital investment of 0.1B yen, indicating the current business model has not demonstrated commercial traction and fundamental strategic pivots or cost restructuring may be forthcoming. Balance sheet composition shift is notable with equity declining 43.8% from 22.6B yen to 12.7B yen while total assets increased 24.9% to 29.4B yen, creating a leverage ratio of 1.32x debt-to-equity that represents a structural shift toward debt financing that will require careful monitoring of covenant compliance and refinancing conditions as the 15.0B yen bond approaches maturity.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.